Virtual Library
Start Your Search
S. Kate
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-021 - A Prospective Observational Study to Evaluate Incidence of Thromboembolic Events during Platinum Based Chemotherapy in Lung Cancer (ID 8131)
09:30 - 09:30 | Author(s): S. Kate
- Abstract
Background:
Lung Cancer is a prothrombotic state with its treatment frequently complicated by thromboembolism leading to shorter life expectancy, worsening of the quality of life and may delay, interrupt, or completely halt the cancer therapy. Based on many retrospectives and prospective analyses in patients with lung cancer, thromboembolic complications are a common event with incidences ranging from 10-17 %. It is possible to identify those with the highest risk of venous thromboembolism suitable for antithrombotic prophylaxis, which could favorably affect their morbidity and mortality
Method:
All patients with advanced lung cancer who were started on platinum-based chemotherapy were included. Those patients who had prior TEs or inherited coagulopathy or those on therapeutic anticoagulation, regular NSAIDs / aspirin or those on bevacizumab were excluded.A thromboembolic event was considered associated with chemotherapy if it occurred between the time of the first dose and 4 weeks after the last dose
Result:
A total 188 patients were screened for the study and 167 patients were enrolled in the study. Since 2 patients were lost to follow-up after accrual, 165 patients were included in the final analysis. Of the 165 patients, 67.8% (112/165) received chemotherapy regimen of carboplatin with gemcitabine, 30.3% (50/167) received carboplatin with pemetrexed, 1.2 % (2/165) received cisplatin with pemetrexed and 0.6 % (1/165) received carboplatin with paclitaxel. A median number of days on platinum were 94 (range 10-478). The median number of chemotherapy cycles administered was 4 (range 1–6). Thromboembolic events occurred in 4.8% of patients (8 out of 165 patients) which were related to the platinum chemotherapy. Among 8 patients with thromboembolic events, 3 patients developed venous pulmonary thromboembolism and 5 patients developed cerebral infarction, out of which 4 had arterial cerebral infarction and one patient had a superior sagittal sinus thrombosis. All eight patients were symptomatic and one patient with cerebral infarction died because of the infarction. The majority of events (7 out of 8) occurred within the first 100 days of starting platinum chemotherapy. Overall, the median time until occurrence of a thromboembolic event was 24 days (range, 8 to 129days). None of the presumed risk factors associated with thrombosis were found be related to the occurrence of TEs on univariate analysis.
Conclusion:
The incidence of thromboembolic events were 4.8 % in our study was low due to the use of carboplatin-based regimens in the majority of patients. The majority of thromboembolic events occurred within 3 months from the initiation of chemotherapy.
